Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model

Rationale ( R,S )-ketamine, an N -methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal ideation in treatment-resistant patients with depression. However, the precise mechanisms underlying the antidepressant actions of ( R,S )-ketami...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacology Vol. 235; no. 11; pp. 3177 - 3185
Main Authors: Zhang, Kai, Toki, Hidetoh, Fujita, Yuko, Ma, Min, Chang, Lijia, Qu, Youge, Harada, Shingo, Nemoto, Tetsuhiro, Mizuno-Yasuhira, Akiko, Yamaguchi, Jun-ichi, Chaki, Shigeyuki, Hashimoto, Kenji
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-11-2018
Springer
Springer Nature B.V
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Rationale ( R,S )-ketamine, an N -methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal ideation in treatment-resistant patients with depression. However, the precise mechanisms underlying the antidepressant actions of ( R,S )-ketamine are unknown. Although the previous report demonstrated the deuterium isotope effects in the antidepressant actions of ( R,S )-ketamine, the deuterium isotope effects in the antidepressant actions of ( R )-ketamine, which is more potent than ( S )-ketamine, are unknown. Methods We examined whether deuterium substitution at the C6 position could affect antidepressant effects of ( R )-ketamine in a chronic social defeat stress (CSDS) model. Results Pharmacokinetic studies showed that levels of (2 R ,6 R )-d 1 -hydroxynorketamine [(2 R ,6 R )-d 1 -HNK], a final metabolite of ( R )-d 2 -ketamine, in the plasma and brain after administration of ( R )-d 2 -ketamine (10 mg/kg) were lower than those of (2 R ,6 R )-HNK from ( R )-ketamine (10 mg/kg), indicating deuterium isotope effects in the production of (2 R ,6 R )-HNK. In contrast, levels of ( R )-ketamine and its metabolite ( R )-norketamine in the plasma and brain were the same for both compounds. In a CSDS model, both ( R )-ketamine (10 mg/kg) and ( R )-d 2 -ketamine (10 mg/kg) showed rapid and long-lasting (7 days) antidepressant effects, indicating no deuterium isotope effect in the antidepressant effects of ( R )-ketamine. Conclusions The present study suggests that deuterium substitution of hydrogen at the C6 position slows the metabolism from ( R )-ketamine to (2 R ,6 R )-HNK in mice. In contrast, we did not find the deuterium isotope effects in terms of the rapid and long-lasting antidepressant effects of ( R )-ketamine in a CSDS model. Therefore, it is unlikely that (2 R ,6 R )-HNK is essential for antidepressant effects of ( R )-ketamine.
AbstractList Rationale (R,S)-ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal ideation in treatment-resistant patients with depression. However, the precise mechanisms underlying the antidepressant actions of (R,S)-ketamine are unknown. Although the previous report demonstrated the deuterium isotope effects in the antidepressant actions of (R,S)-ketamine, the deuterium isotope effects in the antidepressant actions of (R)-ketamine, which is more potent than (S)-ketamine, are unknown. Methods We examined whether deuterium substitution at the C6 position could affect antidepressant effects of (R)-ketamine in a chronic social defeat stress (CSDS) model. Results Pharmacokinetic studies showed that levels of (2R,6R)-d.sub.1-hydroxynorketamine [(2R,6R)-d.sub.1-HNK], a final metabolite of (R)-d.sub.2-ketamine, in the plasma and brain after administration of (R)-d.sub.2-ketamine (10 mg/kg) were lower than those of (2R,6R)-HNK from (R)-ketamine (10 mg/kg), indicating deuterium isotope effects in the production of (2R,6R)-HNK. In contrast, levels of (R)-ketamine and its metabolite (R)-norketamine in the plasma and brain were the same for both compounds. In a CSDS model, both (R)-ketamine (10 mg/kg) and (R)-d.sub.2-ketamine (10 mg/kg) showed rapid and long-lasting (7 days) antidepressant effects, indicating no deuterium isotope effect in the antidepressant effects of (R)-ketamine. Conclusions The present study suggests that deuterium substitution of hydrogen at the C6 position slows the metabolism from (R)-ketamine to (2R,6R)-HNK in mice. In contrast, we did not find the deuterium isotope effects in terms of the rapid and long-lasting antidepressant effects of (R)-ketamine in a CSDS model. Therefore, it is unlikely that (2R,6R)-HNK is essential for antidepressant effects of (R)-ketamine.
(R,S)-ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal ideation in treatment-resistant patients with depression. However, the precise mechanisms underlying the antidepressant actions of (R,S)-ketamine are unknown. Although the previous report demonstrated the deuterium isotope effects in the antidepressant actions of (R,S)-ketamine, the deuterium isotope effects in the antidepressant actions of (R)-ketamine, which is more potent than (S)-ketamine, are unknown. We examined whether deuterium substitution at the C6 position could affect antidepressant effects of (R)-ketamine in a chronic social defeat stress (CSDS) model. Pharmacokinetic studies showed that levels of (2R,6R)-d -hydroxynorketamine [(2R,6R)-d -HNK], a final metabolite of (R)-d -ketamine, in the plasma and brain after administration of (R)-d -ketamine (10 mg/kg) were lower than those of (2R,6R)-HNK from (R)-ketamine (10 mg/kg), indicating deuterium isotope effects in the production of (2R,6R)-HNK. In contrast, levels of (R)-ketamine and its metabolite (R)-norketamine in the plasma and brain were the same for both compounds. In a CSDS model, both (R)-ketamine (10 mg/kg) and (R)-d -ketamine (10 mg/kg) showed rapid and long-lasting (7 days) antidepressant effects, indicating no deuterium isotope effect in the antidepressant effects of (R)-ketamine. The present study suggests that deuterium substitution of hydrogen at the C6 position slows the metabolism from (R)-ketamine to (2R,6R)-HNK in mice. In contrast, we did not find the deuterium isotope effects in terms of the rapid and long-lasting antidepressant effects of (R)-ketamine in a CSDS model. Therefore, it is unlikely that (2R,6R)-HNK is essential for antidepressant effects of (R)-ketamine.
(R,S)-ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal ideation in treatment-resistant patients with depression. However, the precise mechanisms underlying the antidepressant actions of (R,S)-ketamine are unknown. Although the previous report demonstrated the deuterium isotope effects in the antidepressant actions of (R,S)-ketamine, the deuterium isotope effects in the antidepressant actions of (R)-ketamine, which is more potent than (S)-ketamine, are unknown. We examined whether deuterium substitution at the C6 position could affect antidepressant effects of (R)-ketamine in a chronic social defeat stress (CSDS) model. Pharmacokinetic studies showed that levels of (2R,6R)-d.sub.1-hydroxynorketamine [(2R,6R)-d.sub.1-HNK], a final metabolite of (R)-d.sub.2-ketamine, in the plasma and brain after administration of (R)-d.sub.2-ketamine (10 mg/kg) were lower than those of (2R,6R)-HNK from (R)-ketamine (10 mg/kg), indicating deuterium isotope effects in the production of (2R,6R)-HNK. In contrast, levels of (R)-ketamine and its metabolite (R)-norketamine in the plasma and brain were the same for both compounds. In a CSDS model, both (R)-ketamine (10 mg/kg) and (R)-d.sub.2-ketamine (10 mg/kg) showed rapid and long-lasting (7 days) antidepressant effects, indicating no deuterium isotope effect in the antidepressant effects of (R)-ketamine. The present study suggests that deuterium substitution of hydrogen at the C6 position slows the metabolism from (R)-ketamine to (2R,6R)-HNK in mice. In contrast, we did not find the deuterium isotope effects in terms of the rapid and long-lasting antidepressant effects of (R)-ketamine in a CSDS model. Therefore, it is unlikely that (2R,6R)-HNK is essential for antidepressant effects of (R)-ketamine.
Rationale(R,S)-ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal ideation in treatment-resistant patients with depression. However, the precise mechanisms underlying the antidepressant actions of (R,S)-ketamine are unknown. Although the previous report demonstrated the deuterium isotope effects in the antidepressant actions of (R,S)-ketamine, the deuterium isotope effects in the antidepressant actions of (R)-ketamine, which is more potent than (S)-ketamine, are unknown.MethodsWe examined whether deuterium substitution at the C6 position could affect antidepressant effects of (R)-ketamine in a chronic social defeat stress (CSDS) model.ResultsPharmacokinetic studies showed that levels of (2R,6R)-d1-hydroxynorketamine [(2R,6R)-d1-HNK], a final metabolite of (R)-d2-ketamine, in the plasma and brain after administration of (R)-d2-ketamine (10 mg/kg) were lower than those of (2R,6R)-HNK from (R)-ketamine (10 mg/kg), indicating deuterium isotope effects in the production of (2R,6R)-HNK. In contrast, levels of (R)-ketamine and its metabolite (R)-norketamine in the plasma and brain were the same for both compounds. In a CSDS model, both (R)-ketamine (10 mg/kg) and (R)-d2-ketamine (10 mg/kg) showed rapid and long-lasting (7 days) antidepressant effects, indicating no deuterium isotope effect in the antidepressant effects of (R)-ketamine.ConclusionsThe present study suggests that deuterium substitution of hydrogen at the C6 position slows the metabolism from (R)-ketamine to (2R,6R)-HNK in mice. In contrast, we did not find the deuterium isotope effects in terms of the rapid and long-lasting antidepressant effects of (R)-ketamine in a CSDS model. Therefore, it is unlikely that (2R,6R)-HNK is essential for antidepressant effects of (R)-ketamine.
RATIONALE(R,S)-ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal ideation in treatment-resistant patients with depression. However, the precise mechanisms underlying the antidepressant actions of (R,S)-ketamine are unknown. Although the previous report demonstrated the deuterium isotope effects in the antidepressant actions of (R,S)-ketamine, the deuterium isotope effects in the antidepressant actions of (R)-ketamine, which is more potent than (S)-ketamine, are unknown.METHODSWe examined whether deuterium substitution at the C6 position could affect antidepressant effects of (R)-ketamine in a chronic social defeat stress (CSDS) model.RESULTSPharmacokinetic studies showed that levels of (2R,6R)-d1-hydroxynorketamine [(2R,6R)-d1-HNK], a final metabolite of (R)-d2-ketamine, in the plasma and brain after administration of (R)-d2-ketamine (10 mg/kg) were lower than those of (2R,6R)-HNK from (R)-ketamine (10 mg/kg), indicating deuterium isotope effects in the production of (2R,6R)-HNK. In contrast, levels of (R)-ketamine and its metabolite (R)-norketamine in the plasma and brain were the same for both compounds. In a CSDS model, both (R)-ketamine (10 mg/kg) and (R)-d2-ketamine (10 mg/kg) showed rapid and long-lasting (7 days) antidepressant effects, indicating no deuterium isotope effect in the antidepressant effects of (R)-ketamine.CONCLUSIONSThe present study suggests that deuterium substitution of hydrogen at the C6 position slows the metabolism from (R)-ketamine to (2R,6R)-HNK in mice. In contrast, we did not find the deuterium isotope effects in terms of the rapid and long-lasting antidepressant effects of (R)-ketamine in a CSDS model. Therefore, it is unlikely that (2R,6R)-HNK is essential for antidepressant effects of (R)-ketamine.
Rationale ( R,S )-ketamine, an N -methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal ideation in treatment-resistant patients with depression. However, the precise mechanisms underlying the antidepressant actions of ( R,S )-ketamine are unknown. Although the previous report demonstrated the deuterium isotope effects in the antidepressant actions of ( R,S )-ketamine, the deuterium isotope effects in the antidepressant actions of ( R )-ketamine, which is more potent than ( S )-ketamine, are unknown. Methods We examined whether deuterium substitution at the C6 position could affect antidepressant effects of ( R )-ketamine in a chronic social defeat stress (CSDS) model. Results Pharmacokinetic studies showed that levels of (2 R ,6 R )-d 1 -hydroxynorketamine [(2 R ,6 R )-d 1 -HNK], a final metabolite of ( R )-d 2 -ketamine, in the plasma and brain after administration of ( R )-d 2 -ketamine (10 mg/kg) were lower than those of (2 R ,6 R )-HNK from ( R )-ketamine (10 mg/kg), indicating deuterium isotope effects in the production of (2 R ,6 R )-HNK. In contrast, levels of ( R )-ketamine and its metabolite ( R )-norketamine in the plasma and brain were the same for both compounds. In a CSDS model, both ( R )-ketamine (10 mg/kg) and ( R )-d 2 -ketamine (10 mg/kg) showed rapid and long-lasting (7 days) antidepressant effects, indicating no deuterium isotope effect in the antidepressant effects of ( R )-ketamine. Conclusions The present study suggests that deuterium substitution of hydrogen at the C6 position slows the metabolism from ( R )-ketamine to (2 R ,6 R )-HNK in mice. In contrast, we did not find the deuterium isotope effects in terms of the rapid and long-lasting antidepressant effects of ( R )-ketamine in a CSDS model. Therefore, it is unlikely that (2 R ,6 R )-HNK is essential for antidepressant effects of ( R )-ketamine.
Audience Academic
Author Yamaguchi, Jun-ichi
Mizuno-Yasuhira, Akiko
Chaki, Shigeyuki
Fujita, Yuko
Chang, Lijia
Hashimoto, Kenji
Ma, Min
Harada, Shingo
Qu, Youge
Zhang, Kai
Toki, Hidetoh
Nemoto, Tetsuhiro
Author_xml – sequence: 1
  givenname: Kai
  surname: Zhang
  fullname: Zhang, Kai
  organization: Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Wuxi Mental Health Center, Nanjing Medical University
– sequence: 2
  givenname: Hidetoh
  surname: Toki
  fullname: Toki, Hidetoh
  organization: Research Headquarters, Taisho Pharmaceutical Co., Ltd
– sequence: 3
  givenname: Yuko
  surname: Fujita
  fullname: Fujita, Yuko
  organization: Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health
– sequence: 4
  givenname: Min
  surname: Ma
  fullname: Ma, Min
  organization: Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health
– sequence: 5
  givenname: Lijia
  surname: Chang
  fullname: Chang, Lijia
  organization: Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health
– sequence: 6
  givenname: Youge
  surname: Qu
  fullname: Qu, Youge
  organization: Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health
– sequence: 7
  givenname: Shingo
  surname: Harada
  fullname: Harada, Shingo
  organization: Graduate School of Pharmaceutical Sciences, Chiba University
– sequence: 8
  givenname: Tetsuhiro
  surname: Nemoto
  fullname: Nemoto, Tetsuhiro
  organization: Graduate School of Pharmaceutical Sciences, Chiba University
– sequence: 9
  givenname: Akiko
  surname: Mizuno-Yasuhira
  fullname: Mizuno-Yasuhira, Akiko
  organization: Research Headquarters, Taisho Pharmaceutical Co., Ltd
– sequence: 10
  givenname: Jun-ichi
  surname: Yamaguchi
  fullname: Yamaguchi, Jun-ichi
  organization: Research Headquarters, Taisho Pharmaceutical Co., Ltd
– sequence: 11
  givenname: Shigeyuki
  surname: Chaki
  fullname: Chaki, Shigeyuki
  organization: Research Headquarters, Taisho Pharmaceutical Co., Ltd
– sequence: 12
  givenname: Kenji
  surname: Hashimoto
  fullname: Hashimoto, Kenji
  email: hashimoto@faculty.chiba-u.jp
  organization: Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30215218$$D View this record in MEDLINE/PubMed
BookMark eNp1kV1rFDEUhoNU7Lb6A7yRgDf1YtqTr5nZy1LaKiwIUq9DNnPSpp1J1iSD-O-bYWuLognk6zzvS5L3iByEGJCQ9wxOGUB3lgE4Ew2wvlHAuoa_IismBW84dPyArACEaART_SE5yvkeapO9fEMORdUpzvoV-bkx9oFGRwecCyY_T9TnWOIOKTqHtmTqAy13SE0ofsBdwpzr8rlapSffPjUPWMzkAy60ofYuxeAtzdF6M1Zvh6bQXBYxneKA41vy2pkx47un-Zh8v7q8ufjcbL5ef7k43zRWgSqNBLFds84Z3llhXTt0fFAGbC95KzvAbmtlrRscWiGWvZEK-2HNAHupehDH5GTvu0vxx4y56Mlni-NoAsY5a85AQSvXal3Rj3-h93FOod5uoYRol-GFujUjah9cLMnYxVSfq7Z-sOI9q9TpP6jaB5y8rSk6X8__ELC9wKaYc0Knd8lPJv3SDPQStt6HrWvYeglb86r58HTheTvh8Kz4nW4F-B7ItRRuMb286P-uj4s6s1w
CitedBy_id crossref_primary_10_3389_fphar_2024_1337749
crossref_primary_10_1080_14737175_2019_1643237
crossref_primary_10_1016_j_ejphar_2023_176032
crossref_primary_10_1016_j_pbb_2019_04_008
crossref_primary_10_1016_j_neuropharm_2022_109305
crossref_primary_10_1016_j_neuropharm_2022_109348
crossref_primary_10_3390_molecules25184173
crossref_primary_10_1016_j_neuropharm_2022_109378
crossref_primary_10_1177_1179069518815445
crossref_primary_10_3390_molecules25010023
crossref_primary_10_1016_j_bcp_2020_113935
crossref_primary_10_1038_s41380_019_0400_x
crossref_primary_10_1124_pharmrev_120_000149
crossref_primary_10_1016_j_jpba_2022_115168
crossref_primary_10_1111_pcn_12902
crossref_primary_10_1016_j_pbb_2020_172870
crossref_primary_10_1016_j_pbb_2020_172876
crossref_primary_10_1038_s41380_021_01121_1
crossref_primary_10_1007_s00406_024_01809_9
crossref_primary_10_1111_bph_14683
crossref_primary_10_1016_j_bbr_2019_111904
crossref_primary_10_1038_s41398_019_0624_1
crossref_primary_10_1016_j_bbr_2020_112631
crossref_primary_10_1038_s41598_020_61983_3
crossref_primary_10_1080_14737175_2019_1554434
Cites_doi 10.1016/j.biopsych.2017.05.016
10.1016/j.biopsych.2012.03.004
10.1176/appi.ajp.2013.13030392
10.1124/jpet.116.239228
10.1001/jamapsychiatry.2017.0080
10.1176/appi.ajp.2017.17020239
10.1001/archpsyc.63.8.856
10.1016/j.coph.2014.11.005
10.1007/s00406-016-0718-1
10.1016/j.biopsych.2017.01.002
10.1016/j.biopsych.2013.03.026
10.1038/s41386-018-0084-y
10.1038/mp.2017.255
10.1093/ijnp/pyx120
10.2174/1570159X15666170221101054
10.1124/pr.117.015198
10.1080/14728222.2016.1238899
10.1038/nm.4050
10.1038/s41598-018-22449-9
10.1007/s00406-016-0692-7
10.1021/cr50004a004
10.1016/j.drudis.2018.02.006
10.1093/ijnp/pyy053
10.1093/ijnp/pyx108
10.1016/j.psychres.2016.03.034
10.1016/0883-2897(86)90256-4
10.1016/j.jpba.2017.09.033
10.1038/nature17998
10.3109/00498254.2012.685777
10.1176/appi.ajp.2017.17040472
10.1016/j.pbb.2018.07.003
10.1017/S0033291716000064
10.1016/S0006-3223(99)00230-9
10.1001/archgenpsychiatry.2010.90
10.1016/S2215-0366(17)30102-5
10.1093/ijnp/pyx100
10.1038/s41398-017-0031-4
10.1017/S0033291716000969
10.1176/appi.ajp.2015.15040465
10.1016/j.pbb.2013.11.033
10.1093/ijnp/pyv124
10.1016/j.biopsych.2016.12.020
10.1038/tp.2015.136
10.1016/j.conb.2014.12.004
10.1016/0165-6147(84)90534-0
10.1016/S2215-0366(17)30272-9
10.1176/appi.ajp.2016.16040411
10.1016/j.biopsych.2017.12.007
10.1124/dmd.30.7.853
10.1093/ijnp/pyy065
ContentType Journal Article
Copyright Springer-Verlag GmbH Germany, part of Springer Nature 2018
COPYRIGHT 2018 Springer
Psychopharmacology is a copyright of Springer, (2018). All Rights Reserved.
Copyright_xml – notice: Springer-Verlag GmbH Germany, part of Springer Nature 2018
– notice: COPYRIGHT 2018 Springer
– notice: Psychopharmacology is a copyright of Springer, (2018). All Rights Reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7QG
7QR
7RV
7TK
7X7
7XB
88E
88G
8AO
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
K9.
KB0
M0S
M1P
M2M
NAPCQ
P64
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
DOI 10.1007/s00213-018-5017-2
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Animal Behavior Abstracts
Chemoreception Abstracts
Proquest Nursing & Allied Health Source
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
ProQuest Pharma Collection
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
Medical Database
Psychology Database
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest One Psychology
ProQuest Central Student
Technology Research Database
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Chemoreception Abstracts
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
Animal Behavior Abstracts
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE

ProQuest One Psychology
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1432-2072
EndPage 3185
ExternalDocumentID A560045281
10_1007_s00213_018_5017_2
30215218
Genre Journal Article
GrantInformation_xml – fundername: Japan Agency for Medical Research and Development
  grantid: JP18dm0107119
  funderid: http://dx.doi.org/10.13039/100009619
– fundername: Japan Agency for Medical Research and Development
  grantid: JP18dm0107119
GroupedDBID -4W
-BR
.55
3SX
40D
40E
95.
95~
ABMNI
AGWIL
ALMA_UNASSIGNED_HOLDINGS
KOW
N2Q
R9-
RHV
SBY
SOJ
X7M
~EX
---
-56
-5G
-EM
-Y2
-~C
.86
.GJ
.VR
04C
06C
06D
0R~
0VY
123
199
1N0
1SB
2.D
203
28-
29P
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2QV
2VQ
2~H
30V
36B
3O-
3V.
4.4
406
408
409
53G
5QI
5RE
5VS
67N
67Z
6NX
78A
7RV
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
96X
AAAVM
AABHQ
AACDK
AAEOY
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AAQLM
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDBF
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABIVO
ABJNI
ABJOX
ABKCH
ABKTR
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTAH
ABTEG
ABTHY
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACIPQ
ACIWK
ACKNC
ACMDZ
ACMLO
ACNCT
ACOKC
ACOMO
ACPRK
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYPR
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFFNX
AFGCZ
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B-.
B0M
BA0
BBWZM
BDATZ
BENPR
BGNMA
BKEYQ
BMSDO
BPHCQ
BVXVI
CAG
CCPQU
CGR
COF
CS3
CSCUP
CUY
CVF
DDRTE
DL5
DNIVK
DPUIP
DU5
DWQXO
DXH
EAD
EAP
EBC
EBD
EBLON
EBS
ECM
EIF
EIHBH
EIOEI
EJD
EMB
EMK
EMOBN
EN4
EPAXT
EPL
EPS
ESBYG
ESX
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNUQQ
GNWQR
GQ6
GQ7
GQ8
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IAO
ICJ
IHE
IHR
IJ-
IKXTQ
IMOTQ
INH
INR
IPY
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KPH
LAS
LLZTM
M1P
M2M
M4Y
MA-
MK0
N9A
NAPCQ
NB0
NDZJH
NPM
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
P2P
PF-
PQQKQ
PROAC
PSQYO
PSYQQ
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RIG
RNI
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S3A
S3B
SAP
SBL
SCLPG
SDH
SDM
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZN
T13
T16
TN5
TSG
TSK
TSV
TUC
TUS
U2A
U9L
UAP
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WH7
WIP
WJK
WK6
WK8
WOW
XOL
YLTOR
YQJ
YYP
Z45
Z7U
Z7W
Z82
Z83
Z87
Z8O
Z8Q
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
ZY4
~8M
AAYXX
CITATION
7QG
7QR
7TK
7XB
8FD
8FK
FR3
K9.
P64
PQEST
PQUKI
PRINS
Q9U
7X8
ID FETCH-LOGICAL-c505t-403b917fa27c3cf6d72d5a0c8426470e7bc4917aed63370e7a45e8d910e845803
IEDL.DBID AEJHL
ISSN 0033-3158
IngestDate Fri Oct 25 22:07:13 EDT 2024
Thu Oct 10 16:49:31 EDT 2024
Tue Nov 19 21:21:30 EST 2024
Tue Nov 12 23:31:57 EST 2024
Fri Aug 23 01:56:17 EDT 2024
Wed Oct 16 00:50:45 EDT 2024
Wed Oct 12 10:50:01 EDT 2022
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords 2
Deuterium isotope effect
ketamine
6
(
hydroxynorketamine
Metabolism
(2R,6R)-hydroxynorketamine
(R)-ketamine
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c505t-403b917fa27c3cf6d72d5a0c8426470e7bc4917aed63370e7a45e8d910e845803
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 30215218
PQID 2103361033
PQPubID 47309
PageCount 9
ParticipantIDs proquest_miscellaneous_2105064959
proquest_journals_2103361033
gale_infotracmisc_A560045281
gale_infotracacademiconefile_A560045281
crossref_primary_10_1007_s00213_018_5017_2
pubmed_primary_30215218
springer_journals_10_1007_s00213_018_5017_2
PublicationCentury 2000
PublicationDate 2018-11-01
PublicationDateYYYYMMDD 2018-11-01
PublicationDate_xml – month: 11
  year: 2018
  text: 2018-11-01
  day: 01
PublicationDecade 2010
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle Psychopharmacology
PublicationTitleAbbrev Psychopharmacology
PublicationTitleAlternate Psychopharmacology (Berl)
PublicationYear 2018
Publisher Springer Berlin Heidelberg
Springer
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer
– name: Springer Nature B.V
References Hashimoto, Kakiuchi, Ohba, Nishiyama, Tsukada (CR17) 2017; 267
CR35
Hashimoto (CR14) 2016; 173
Sanacora, Frye, McDonald, Mathew, Turner, Schatzberg, Summergrad, Nemeroff (CR25) 2017; 74
Yang, Ren, Qu, Zhang, Ma, Dong, Hashimoto (CR42) 2018; 83
Hashimoto (CR12) 2016; 46
Wilkinson, Ballard, Bloch, Mathew, Murrough, Feder, Sos, Wang, Zarate, Sanacora (CR34) 2018; 175
Chaki (CR3) 2017; 15
Shirayama, Hashimoto (CR26) 2017; 267
Wiberg (CR32) 1955; 55
Xu, Hackett, Carter, Loo, Gálvez, Glozier, Glue, Lapidus, McGirr, Somogyi, Mitchell, Rodgers (CR36) 2016; 19
Chaki (CR4) 2018; 21
Hashimoto, Shirayama (CR15) 2018; 84
Zarate, Singh, Carlson, Brutsche, Ameli, Luckenbaugh, Charney, Manji (CR46) 2006; 63
Hashimoto (CR13) 2016; 20
Berman, Cappiello, Anand, Oren, Heninger, Charney, Krystal (CR2) 2000; 47
Zhang, Li, Hashimoto (CR48) 2014; 116
Yang, Shirayama, Zhang, Ren, Yao, Ma, Dong, Hashimoto (CR38) 2015; 5
Foster (CR9) 1984; 5
Wilkinson, Toprak, Turner, Levine, Katz, Sanacora (CR33) 2017; 174
Desta, Moaddel, Ogburn, Xu, Ramamoorthy, Venkata, Sanghvi, Goldberg, Torjman, Wainer (CR6) 2012; 42
Shirayama, Hashimoto (CR27) 2018; 21
Zanos, Moaddel, Morris, Georgiou, Fischell, Elmer, Alkondon, Yuan, Pribut, Singh, Dossou, Fang, Huang, Mayo, Wainer, Albuquerque, Thompson, Thomas, Zarate, Gould (CR44) 2016; 533
Zhang, Fujita, Hashimoto (CR50) 2018; 8
Fukumoto, Toki, Iijima, Hashihayata, Yamaguchi, Hashimoto, Chaki (CR10) 2017; 361
Kavalali, Monteggia (CR19) 2015; 20
Diazgranados, Ibrahim, Brutsche, Newberg, Kronstein, Khalife, Kammerer, Quezado, Luckenbaugh, Salvadore, Machado-Vieira, Manji, Zarate (CR7) 2010; 67
Zhang, Dong, Fujita, Fujita, Hashimoto (CR49) 2018; 21
Newport, Carpenter, WM, Potash, Tohen, Nemeroff (CR24) 2015; 172
CR51
Chang, Toki, Qu, Fujita, Mizuno-Yasuhira, Yamaguchi, Chaki, Hashimoto (CR5) 2018; 21
Hashimoto, Inoue, Suzuki, Yamasaki, Kojima (CR16) 1986; 13
Zanos, Gould (CR43) 2018; 23
Zanos, Moaddel, Morris, Riggs, Highland, Georgiou, Pereira, Albuquerque, Thomas, Zarate, Gould (CR45) 2018; 70
Short, Fong, Galvez, Shelker, Loo (CR28) 2018; 5
Yamaguchi, Toki, Qu, Yang, Koike, Hashimoto, Mizuno-Yasuhira, Chaki (CR37) 2018; 43
Duman, Aghajanian, Sanacora, Krystal (CR8) 2016; 22
Yang, Qu, Abe, Nozawa, Chaki, Hashimoto (CR40) 2017; 82
Abdallah (CR1) 2017; 81
Kishimoto, Chawla, Hagi, Zarate, Kane, Bauer, Correll (CR20) 2016; 46
Singh, Morgan, Curran, Nutt, Schlag, McShane (CR29) 2017; 4
Tian, Dong, Fujita, Fujita, Hashimoto (CR30) 2018; 172
Monteggia, Zarate (CR22) 2015; 30
Yang, Han, Zhang, Ren, Hashimoto (CR39) 2016; 239
Yang, Qu, Fujita, Ren, Ma, Dong, Hashimoto (CR41) 2017; 7
Hijazi, Boulieu (CR18) 2002; 30
Krystal, Sanacora, Duman (CR21) 2013; 73
Murrough, Iosifescu, Chang, Al Jurdi, Green, Perez, Iqbal, Pillemer, Foulkes, Shah, Charney, Mathew (CR23) 2013; 170
Garay, Zarate, Cavero, Kim, Charpeaud, Skolnick (CR11) 2018; 23
Zarate, Brutsche, Ibrahim, Franco-Chaves, Diazgranados, Cravchik, Selter, Marquardt, Liberty, Luckenbaugh (CR47) 2012; 72
Toki, Ichikawa, Mizuno-Yasuhara, Yamaguchi (CR31) 2018; 148
JW Murrough (5017_CR23) 2013; 170
Ricardo Garay (5017_CR11) 2018; 23
Lijia Chang (5017_CR5) 2018; 21
K Hashimoto (5017_CR16) 1986; 13
C Yang (5017_CR40) 2017; 82
K Hashimoto (5017_CR14) 2016; 173
5017_CR35
K Zhang (5017_CR49) 2018; 21
N Diazgranados (5017_CR7) 2010; 67
J Yamaguchi (5017_CR37) 2018; 43
H Toki (5017_CR31) 2018; 148
LM Monteggia (5017_CR22) 2015; 30
Y Xu (5017_CR36) 2016; 19
CA Zarate Jr (5017_CR47) 2012; 72
B Short (5017_CR28) 2018; 5
Y Shirayama (5017_CR26) 2017; 267
CG Abdallah (5017_CR1) 2017; 81
RM Berman (5017_CR2) 2000; 47
DJ Newport (5017_CR24) 2015; 172
C Yang (5017_CR42) 2018; 83
S Chaki (5017_CR3) 2017; 15
K Fukumoto (5017_CR10) 2017; 361
T Kishimoto (5017_CR20) 2016; 46
K Zhang (5017_CR50) 2018; 8
K Hashimoto (5017_CR12) 2016; 46
AB Foster (5017_CR9) 1984; 5
ST Wilkinson (5017_CR33) 2017; 174
Z Tian (5017_CR30) 2018; 172
RS Duman (5017_CR8) 2016; 22
ET Kavalali (5017_CR19) 2015; 20
JH Krystal (5017_CR21) 2013; 73
K Hashimoto (5017_CR15) 2018; 84
Y Shirayama (5017_CR27) 2018; 21
P Zanos (5017_CR43) 2018; 23
KB Wiberg (5017_CR32) 1955; 55
I Singh (5017_CR29) 2017; 4
C Yang (5017_CR38) 2015; 5
C Yang (5017_CR39) 2016; 239
P Zanos (5017_CR44) 2016; 533
Z Desta (5017_CR6) 2012; 42
Y Hijazi (5017_CR18) 2002; 30
K Hashimoto (5017_CR17) 2017; 267
5017_CR51
K Hashimoto (5017_CR13) 2016; 20
CA Zarate Jr (5017_CR46) 2006; 63
S Chaki (5017_CR4) 2018; 21
P Zanos (5017_CR45) 2018; 70
ST Wilkinson (5017_CR34) 2018; 175
JC Zhang (5017_CR48) 2014; 116
G Sanacora (5017_CR25) 2017; 74
C Yang (5017_CR41) 2017; 7
References_xml – volume: 83
  start-page: 18
  year: 2018
  end-page: 28
  ident: CR42
  article-title: Mechanistic target of rapamycin-independent antidepressant effects of ( )-ketamine in a social defeat stress model
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2017.05.016
  contributor:
    fullname: Hashimoto
– volume: 72
  start-page: 331
  year: 2012
  end-page: 338
  ident: CR47
  article-title: Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2012.03.004
  contributor:
    fullname: Luckenbaugh
– volume: 170
  start-page: 1134
  year: 2013
  end-page: 1142
  ident: CR23
  article-title: Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2013.13030392
  contributor:
    fullname: Mathew
– volume: 361
  start-page: 9
  year: 2017
  end-page: 16
  ident: CR10
  article-title: Antidepressant potential of ( )-ketamine in rodent models: comparison with ( )-ketamine
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.116.239228
  contributor:
    fullname: Chaki
– ident: CR51
– volume: 74
  start-page: 399
  year: 2017
  end-page: 405
  ident: CR25
  article-title: A consensus statement on the use of ketamine in the treatment of mood disorders
  publication-title: JAMA Psychiatry
  doi: 10.1001/jamapsychiatry.2017.0080
  contributor:
    fullname: Nemeroff
– volume: 174
  start-page: 695
  year: 2017
  end-page: 696
  ident: CR33
  article-title: A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2017.17020239
  contributor:
    fullname: Sanacora
– volume: 63
  start-page: 856
  year: 2006
  end-page: 864
  ident: CR46
  article-title: A randomized trial of an -methyl-D-aspartate antagonist in treatment-resistant major depression
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.63.8.856
  contributor:
    fullname: Manji
– volume: 20
  start-page: 35
  year: 2015
  end-page: 39
  ident: CR19
  article-title: How does ketamine elicit a rapid antidepressant response?
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/j.coph.2014.11.005
  contributor:
    fullname: Monteggia
– ident: CR35
– volume: 267
  start-page: 177
  year: 2017
  end-page: 182
  ident: CR26
  article-title: Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression
  publication-title: Eur Arch Psychiatry Clin Neurosci
  doi: 10.1007/s00406-016-0718-1
  contributor:
    fullname: Hashimoto
– volume: 81
  start-page: e61
  year: 2017
  end-page: e63
  ident: CR1
  article-title: What’s the buzz about hydroxynorketamine? Is it the history, the story, the debate, or the promise?
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2017.01.002
  contributor:
    fullname: Abdallah
– volume: 73
  start-page: 1133
  year: 2013
  end-page: 1141
  ident: CR21
  article-title: Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2013.03.026
  contributor:
    fullname: Duman
– volume: 43
  start-page: 1900
  year: 2018
  end-page: 1907
  ident: CR37
  article-title: (2 ,6 )-Hydroxynorketamine is not essential for the antidepressant actions of ( )-ketamine in mice
  publication-title: Neuropsychopharmacology
  doi: 10.1038/s41386-018-0084-y
  contributor:
    fullname: Chaki
– volume: 23
  start-page: 801
  year: 2018
  end-page: 811
  ident: CR43
  article-title: Mechanisms of ketamine action as an antidepressant
  publication-title: Mol Psychiatry
  doi: 10.1038/mp.2017.255
  contributor:
    fullname: Gould
– volume: 21
  start-page: 154
  year: 2018
  end-page: 156
  ident: CR4
  article-title: Is metabolism of ( )-ketamine essential for the antidepressant effects?
  publication-title: Int J Neuropsychopharmacol
  doi: 10.1093/ijnp/pyx120
  contributor:
    fullname: Chaki
– volume: 15
  start-page: 963
  year: 2017
  end-page: 976
  ident: CR3
  article-title: Beyond ketamine: new approaches to the development of safer antidepressants
  publication-title: Curr Neuropharmacol
  doi: 10.2174/1570159X15666170221101054
  contributor:
    fullname: Chaki
– volume: 70
  start-page: 621
  year: 2018
  end-page: 660
  ident: CR45
  article-title: Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.117.015198
  contributor:
    fullname: Gould
– volume: 20
  start-page: 1389
  year: 2016
  end-page: 1392
  ident: CR13
  article-title: Ketamine’s antidepressant action: beyond NMDA receptor inhibition
  publication-title: Expert Opin Ther Targets
  doi: 10.1080/14728222.2016.1238899
  contributor:
    fullname: Hashimoto
– volume: 22
  start-page: 238
  year: 2016
  end-page: 249
  ident: CR8
  article-title: Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
  publication-title: Nat Med
  doi: 10.1038/nm.4050
  contributor:
    fullname: Krystal
– volume: 8
  start-page: 4007
  year: 2018
  ident: CR50
  article-title: Lack of metabolism in ( )-ketamine’s antidepressant actions in a chronic social defeat stress model
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-22449-9
  contributor:
    fullname: Hashimoto
– volume: 267
  start-page: 173
  year: 2017
  end-page: 176
  ident: CR17
  article-title: Reduction of dopamine D receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys
  publication-title: Eur Arch Psychiatry Clin Neurosci
  doi: 10.1007/s00406-016-0692-7
  contributor:
    fullname: Tsukada
– volume: 55
  start-page: 713
  year: 1955
  end-page: 743
  ident: CR32
  article-title: The deuterium isotope effect
  publication-title: Chem Rev
  doi: 10.1021/cr50004a004
  contributor:
    fullname: Wiberg
– volume: 23
  start-page: 1689
  issue: 10
  year: 2018
  end-page: 1692
  ident: CR11
  article-title: The development of glutamate-based antidepressants is taking longer than expected
  publication-title: Drug Discovery Today
  doi: 10.1016/j.drudis.2018.02.006
  contributor:
    fullname: Skolnick
– volume: 21
  start-page: 932
  issue: 10
  year: 2018
  end-page: 937
  ident: CR5
  article-title: No Sex-Specific Differences in the Acute Antidepressant Actions of (R)-Ketamine in an Inflammation Model
  publication-title: International Journal of Neuropsychopharmacology
  doi: 10.1093/ijnp/pyy053
  contributor:
    fullname: Hashimoto
– volume: 21
  start-page: 84
  year: 2018
  end-page: 88
  ident: CR27
  article-title: Lack of antidepressant effects of (2 ,6 )-hydroxynorketamine in a rat learned helplessness model: comparison with ( )-ketamine
  publication-title: Int J Neuropsychopharmacol
  doi: 10.1093/ijnp/pyx108
  contributor:
    fullname: Hashimoto
– volume: 239
  start-page: 281
  year: 2016
  end-page: 283
  ident: CR39
  article-title: Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine
  publication-title: Psychiatry Res
  doi: 10.1016/j.psychres.2016.03.034
  contributor:
    fullname: Hashimoto
– volume: 13
  start-page: 79
  year: 1986
  end-page: 80
  ident: CR16
  article-title: Deuterium isotope effect of [ C]N,N-dimethylphenethylamine-α,α-d : reduction in metabolic trapping rate in brain
  publication-title: Int J Rad Appl Instrum B
  doi: 10.1016/0883-2897(86)90256-4
  contributor:
    fullname: Kojima
– volume: 148
  start-page: 288
  year: 2018
  end-page: 297
  ident: CR31
  article-title: A rapid and sensitive chiral LC-MS/MS method for the determination of ketamine and norketamine in mouse plasma, brain and cerebrospinal fluid applicable to the stereoselective pharmacokinetic study of ketamine
  publication-title: J Pharm Biomed Anal
  doi: 10.1016/j.jpba.2017.09.033
  contributor:
    fullname: Yamaguchi
– volume: 533
  start-page: 481
  year: 2016
  end-page: 486
  ident: CR44
  article-title: NMDAR inhibition-independent antidepressant actions of ketamine metabolites
  publication-title: Nature
  doi: 10.1038/nature17998
  contributor:
    fullname: Gould
– volume: 42
  start-page: 1076
  year: 2012
  end-page: 1087
  ident: CR6
  article-title: Stereoselective and regiospecific hydroxylation of ketamine and norketamine
  publication-title: Xenobiotica
  doi: 10.3109/00498254.2012.685777
  contributor:
    fullname: Wainer
– volume: 175
  start-page: 150
  year: 2018
  end-page: 158
  ident: CR34
  article-title: The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2017.17040472
  contributor:
    fullname: Sanacora
– volume: 172
  start-page: 17
  year: 2018
  end-page: 21
  ident: CR30
  article-title: Expression of heat shock protein HSP-70 in the rerosplenial cortex of rat brain after administration of ( )-ketamine and ( )-ketamine, but not ( )-ketamine
  publication-title: Pharmacol Biochem Behav
  doi: 10.1016/j.pbb.2018.07.003
  contributor:
    fullname: Hashimoto
– volume: 46
  start-page: 1459
  year: 2016
  end-page: 1472
  ident: CR20
  article-title: Single-dose infusion ketamine and non-ketamine -methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories
  publication-title: Psychol Med
  doi: 10.1017/S0033291716000064
  contributor:
    fullname: Correll
– volume: 47
  start-page: 351
  year: 2000
  end-page: 354
  ident: CR2
  article-title: Antidepressant effects of ketamine in depressed patients
  publication-title: Biol Psychiatry
  doi: 10.1016/S0006-3223(99)00230-9
  contributor:
    fullname: Krystal
– volume: 67
  start-page: 793
  year: 2010
  end-page: 802
  ident: CR7
  article-title: A randomized add-on trial of an -methyl-D-aspartate antagonist in treatment-resistant bipolar depression
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archgenpsychiatry.2010.90
  contributor:
    fullname: Zarate
– volume: 4
  start-page: 419
  year: 2017
  end-page: 426
  ident: CR29
  article-title: Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight
  publication-title: Lancet Psychiatry
  doi: 10.1016/S2215-0366(17)30102-5
  contributor:
    fullname: McShane
– volume: 21
  start-page: 157
  year: 2018
  end-page: 163
  ident: CR49
  article-title: 5-Hydroxytryptamine-independent antidepressant actions of ( )-ketamine in a chronic social defeat stress model
  publication-title: Int J Neuropsychopharmacol
  doi: 10.1093/ijnp/pyx100
  contributor:
    fullname: Hashimoto
– volume: 7
  start-page: 1294
  year: 2017
  ident: CR41
  article-title: Possible role of the gut microbiota-brain axis in the antidepressant effects of ( )-ketamine sin a social defeat stress model
  publication-title: Transl Psychiatry
  doi: 10.1038/s41398-017-0031-4
  contributor:
    fullname: Hashimoto
– volume: 46
  start-page: 2449
  year: 2016
  end-page: 2451
  ident: CR12
  article-title: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity
  publication-title: Psychol Med
  doi: 10.1017/S0033291716000969
  contributor:
    fullname: Hashimoto
– volume: 172
  start-page: 950
  year: 2015
  end-page: 966
  ident: CR24
  article-title: Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2015.15040465
  contributor:
    fullname: Nemeroff
– volume: 116
  start-page: 137
  year: 2014
  end-page: 141
  ident: CR48
  article-title: R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine
  publication-title: Pharmacol Biochem Behav
  doi: 10.1016/j.pbb.2013.11.033
  contributor:
    fullname: Hashimoto
– volume: 19
  year: 2016
  ident: CR36
  article-title: Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis
  publication-title: Int J Neuropsychopharmacol
  doi: 10.1093/ijnp/pyv124
  contributor:
    fullname: Rodgers
– volume: 82
  start-page: e43
  year: 2017
  end-page: e44
  ident: CR40
  article-title: ( )-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2 ,6 )-hydroxynorketamine
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2016.12.020
  contributor:
    fullname: Hashimoto
– volume: 5
  start-page: e632
  year: 2015
  ident: CR38
  article-title: R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
  publication-title: Transl Psychiatry
  doi: 10.1038/tp.2015.136
  contributor:
    fullname: Hashimoto
– volume: 30
  start-page: 139
  year: 2015
  end-page: 143
  ident: CR22
  article-title: Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
  publication-title: Curr Opin Neurobiol
  doi: 10.1016/j.conb.2014.12.004
  contributor:
    fullname: Zarate
– volume: 5
  start-page: 524
  year: 1984
  end-page: 527
  ident: CR9
  article-title: Deuterium isotope effects in studies of drug metabolism
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/0165-6147(84)90534-0
  contributor:
    fullname: Foster
– volume: 5
  start-page: 65
  year: 2018
  end-page: 78
  ident: CR28
  article-title: Side-effects associated with ketamine use in depression: a systematic review
  publication-title: Lancet Psychiatry
  doi: 10.1016/S2215-0366(17)30272-9
  contributor:
    fullname: Loo
– volume: 173
  start-page: 1044
  year: 2016
  end-page: 1045
  ident: CR14
  article-title: Detrimental side effects of repeated ketamine infusions in the brain
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2016.16040411
  contributor:
    fullname: Hashimoto
– volume: 84
  start-page: e7
  year: 2018
  end-page: e8
  ident: CR15
  article-title: What are the causes for discrepancies of antidepressant actions of (2 ,6 )-hydroxynorketamine?
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2017.12.007
  contributor:
    fullname: Shirayama
– volume: 30
  start-page: 853
  year: 2002
  end-page: 858
  ident: CR18
  article-title: Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to -demethylation of ketamine in human liver microsomes
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.30.7.853
  contributor:
    fullname: Boulieu
– volume: 20
  start-page: 1389
  year: 2016
  ident: 5017_CR13
  publication-title: Expert Opin Ther Targets
  doi: 10.1080/14728222.2016.1238899
  contributor:
    fullname: K Hashimoto
– volume: 170
  start-page: 1134
  year: 2013
  ident: 5017_CR23
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2013.13030392
  contributor:
    fullname: JW Murrough
– volume: 172
  start-page: 950
  year: 2015
  ident: 5017_CR24
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2015.15040465
  contributor:
    fullname: DJ Newport
– volume: 148
  start-page: 288
  year: 2018
  ident: 5017_CR31
  publication-title: J Pharm Biomed Anal
  doi: 10.1016/j.jpba.2017.09.033
  contributor:
    fullname: H Toki
– volume: 55
  start-page: 713
  year: 1955
  ident: 5017_CR32
  publication-title: Chem Rev
  doi: 10.1021/cr50004a004
  contributor:
    fullname: KB Wiberg
– volume: 46
  start-page: 2449
  year: 2016
  ident: 5017_CR12
  publication-title: Psychol Med
  doi: 10.1017/S0033291716000969
  contributor:
    fullname: K Hashimoto
– volume: 70
  start-page: 621
  year: 2018
  ident: 5017_CR45
  publication-title: Pharmacol Rev
  doi: 10.1124/pr.117.015198
  contributor:
    fullname: P Zanos
– volume: 73
  start-page: 1133
  year: 2013
  ident: 5017_CR21
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2013.03.026
  contributor:
    fullname: JH Krystal
– volume: 174
  start-page: 695
  year: 2017
  ident: 5017_CR33
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2017.17020239
  contributor:
    fullname: ST Wilkinson
– ident: 5017_CR35
– ident: 5017_CR51
  doi: 10.1093/ijnp/pyy065
– volume: 239
  start-page: 281
  year: 2016
  ident: 5017_CR39
  publication-title: Psychiatry Res
  doi: 10.1016/j.psychres.2016.03.034
  contributor:
    fullname: C Yang
– volume: 175
  start-page: 150
  year: 2018
  ident: 5017_CR34
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2017.17040472
  contributor:
    fullname: ST Wilkinson
– volume: 13
  start-page: 79
  year: 1986
  ident: 5017_CR16
  publication-title: Int J Rad Appl Instrum B
  doi: 10.1016/0883-2897(86)90256-4
  contributor:
    fullname: K Hashimoto
– volume: 15
  start-page: 963
  year: 2017
  ident: 5017_CR3
  publication-title: Curr Neuropharmacol
  doi: 10.2174/1570159X15666170221101054
  contributor:
    fullname: S Chaki
– volume: 4
  start-page: 419
  year: 2017
  ident: 5017_CR29
  publication-title: Lancet Psychiatry
  doi: 10.1016/S2215-0366(17)30102-5
  contributor:
    fullname: I Singh
– volume: 5
  start-page: 524
  year: 1984
  ident: 5017_CR9
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/0165-6147(84)90534-0
  contributor:
    fullname: AB Foster
– volume: 5
  start-page: 65
  year: 2018
  ident: 5017_CR28
  publication-title: Lancet Psychiatry
  doi: 10.1016/S2215-0366(17)30272-9
  contributor:
    fullname: B Short
– volume: 74
  start-page: 399
  year: 2017
  ident: 5017_CR25
  publication-title: JAMA Psychiatry
  doi: 10.1001/jamapsychiatry.2017.0080
  contributor:
    fullname: G Sanacora
– volume: 46
  start-page: 1459
  year: 2016
  ident: 5017_CR20
  publication-title: Psychol Med
  doi: 10.1017/S0033291716000064
  contributor:
    fullname: T Kishimoto
– volume: 22
  start-page: 238
  year: 2016
  ident: 5017_CR8
  publication-title: Nat Med
  doi: 10.1038/nm.4050
  contributor:
    fullname: RS Duman
– volume: 72
  start-page: 331
  year: 2012
  ident: 5017_CR47
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2012.03.004
  contributor:
    fullname: CA Zarate Jr
– volume: 81
  start-page: e61
  year: 2017
  ident: 5017_CR1
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2017.01.002
  contributor:
    fullname: CG Abdallah
– volume: 21
  start-page: 157
  year: 2018
  ident: 5017_CR49
  publication-title: Int J Neuropsychopharmacol
  doi: 10.1093/ijnp/pyx100
  contributor:
    fullname: K Zhang
– volume: 30
  start-page: 853
  year: 2002
  ident: 5017_CR18
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.30.7.853
  contributor:
    fullname: Y Hijazi
– volume: 83
  start-page: 18
  year: 2018
  ident: 5017_CR42
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2017.05.016
  contributor:
    fullname: C Yang
– volume: 267
  start-page: 173
  year: 2017
  ident: 5017_CR17
  publication-title: Eur Arch Psychiatry Clin Neurosci
  doi: 10.1007/s00406-016-0692-7
  contributor:
    fullname: K Hashimoto
– volume: 21
  start-page: 154
  year: 2018
  ident: 5017_CR4
  publication-title: Int J Neuropsychopharmacol
  doi: 10.1093/ijnp/pyx120
  contributor:
    fullname: S Chaki
– volume: 116
  start-page: 137
  year: 2014
  ident: 5017_CR48
  publication-title: Pharmacol Biochem Behav
  doi: 10.1016/j.pbb.2013.11.033
  contributor:
    fullname: JC Zhang
– volume: 82
  start-page: e43
  year: 2017
  ident: 5017_CR40
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2016.12.020
  contributor:
    fullname: C Yang
– volume: 23
  start-page: 801
  year: 2018
  ident: 5017_CR43
  publication-title: Mol Psychiatry
  doi: 10.1038/mp.2017.255
  contributor:
    fullname: P Zanos
– volume: 84
  start-page: e7
  year: 2018
  ident: 5017_CR15
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2017.12.007
  contributor:
    fullname: K Hashimoto
– volume: 361
  start-page: 9
  year: 2017
  ident: 5017_CR10
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.116.239228
  contributor:
    fullname: K Fukumoto
– volume: 43
  start-page: 1900
  year: 2018
  ident: 5017_CR37
  publication-title: Neuropsychopharmacology
  doi: 10.1038/s41386-018-0084-y
  contributor:
    fullname: J Yamaguchi
– volume: 173
  start-page: 1044
  year: 2016
  ident: 5017_CR14
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.2016.16040411
  contributor:
    fullname: K Hashimoto
– volume: 21
  start-page: 932
  issue: 10
  year: 2018
  ident: 5017_CR5
  publication-title: International Journal of Neuropsychopharmacology
  doi: 10.1093/ijnp/pyy053
  contributor:
    fullname: Lijia Chang
– volume: 30
  start-page: 139
  year: 2015
  ident: 5017_CR22
  publication-title: Curr Opin Neurobiol
  doi: 10.1016/j.conb.2014.12.004
  contributor:
    fullname: LM Monteggia
– volume: 267
  start-page: 177
  year: 2017
  ident: 5017_CR26
  publication-title: Eur Arch Psychiatry Clin Neurosci
  doi: 10.1007/s00406-016-0718-1
  contributor:
    fullname: Y Shirayama
– volume: 20
  start-page: 35
  year: 2015
  ident: 5017_CR19
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/j.coph.2014.11.005
  contributor:
    fullname: ET Kavalali
– volume: 8
  start-page: 4007
  year: 2018
  ident: 5017_CR50
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-22449-9
  contributor:
    fullname: K Zhang
– volume: 172
  start-page: 17
  year: 2018
  ident: 5017_CR30
  publication-title: Pharmacol Biochem Behav
  doi: 10.1016/j.pbb.2018.07.003
  contributor:
    fullname: Z Tian
– volume: 63
  start-page: 856
  year: 2006
  ident: 5017_CR46
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.63.8.856
  contributor:
    fullname: CA Zarate Jr
– volume: 42
  start-page: 1076
  year: 2012
  ident: 5017_CR6
  publication-title: Xenobiotica
  doi: 10.3109/00498254.2012.685777
  contributor:
    fullname: Z Desta
– volume: 23
  start-page: 1689
  issue: 10
  year: 2018
  ident: 5017_CR11
  publication-title: Drug Discovery Today
  doi: 10.1016/j.drudis.2018.02.006
  contributor:
    fullname: Ricardo Garay
– volume: 21
  start-page: 84
  year: 2018
  ident: 5017_CR27
  publication-title: Int J Neuropsychopharmacol
  doi: 10.1093/ijnp/pyx108
  contributor:
    fullname: Y Shirayama
– volume: 67
  start-page: 793
  year: 2010
  ident: 5017_CR7
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archgenpsychiatry.2010.90
  contributor:
    fullname: N Diazgranados
– volume: 7
  start-page: 1294
  year: 2017
  ident: 5017_CR41
  publication-title: Transl Psychiatry
  doi: 10.1038/s41398-017-0031-4
  contributor:
    fullname: C Yang
– volume: 5
  start-page: e632
  year: 2015
  ident: 5017_CR38
  publication-title: Transl Psychiatry
  doi: 10.1038/tp.2015.136
  contributor:
    fullname: C Yang
– volume: 47
  start-page: 351
  year: 2000
  ident: 5017_CR2
  publication-title: Biol Psychiatry
  doi: 10.1016/S0006-3223(99)00230-9
  contributor:
    fullname: RM Berman
– volume: 19
  year: 2016
  ident: 5017_CR36
  publication-title: Int J Neuropsychopharmacol
  doi: 10.1093/ijnp/pyv124
  contributor:
    fullname: Y Xu
– volume: 533
  start-page: 481
  year: 2016
  ident: 5017_CR44
  publication-title: Nature
  doi: 10.1038/nature17998
  contributor:
    fullname: P Zanos
SSID ssj0000484
ssj0068394
Score 2.4666812
Snippet Rationale ( R,S )-ketamine, an N -methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal...
(R,S)-ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal ideation in...
Rationale (R,S)-ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal...
Rationale(R,S)-ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal ideation...
RATIONALE(R,S)-ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits rapid and long-lasting antidepressant effects and anti-suicidal ideation...
SourceID proquest
gale
crossref
pubmed
springer
SourceType Aggregation Database
Index Database
Publisher
StartPage 3177
SubjectTerms Analysis
Animals
Antidepressants
Antidepressive Agents - administration & dosage
Antidepressive Agents - chemistry
Antidepressive Agents - metabolism
Antidepressive Agents - pharmacology
Biomedical and Life Sciences
Biomedicine
Brain
Brain - drug effects
Brain - metabolism
Care and treatment
Chronic Disease
Depression (Mood disorder)
Depression - drug therapy
Depression - metabolism
Depression - psychology
Deuterium
Deuterium - administration & dosage
Deuterium - chemistry
Deuterium - metabolism
Disease Models, Animal
Dosage and administration
Glutamic acid receptors
Isotope effect
Isotopes
Ketamine
Ketamine - administration & dosage
Ketamine - analogs & derivatives
Ketamine - chemistry
Ketamine - metabolism
Male
Mental depression
Metabolism
Mice
Mice, Inbred C57BL
N-Methyl-D-aspartic acid receptors
Neurosciences
Original Investigation
Pharmacology/Toxicology
Psychiatry
Social interactions
Stress, Psychological - drug therapy
Stress, Psychological - metabolism
Stress, Psychological - psychology
Treatment Outcome
Title Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model
URI https://link.springer.com/article/10.1007/s00213-018-5017-2
https://www.ncbi.nlm.nih.gov/pubmed/30215218
https://www.proquest.com/docview/2103361033
https://search.proquest.com/docview/2105064959
Volume 235
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED8NkBAv-2CwhbHJSBPjo5mCnTTOY7UVVYhNiIHEm-U6tlRVJIimQvz3u4uTdEXjYXuJEvkrts93Z9_dzwCfLdeOzENhnoo0jLWMwkxEJtQ8cyiejIxqZ8zRr_Tnjfw-JJgc3h1dFNOvrUWyZtRdrBtJI3L9kWFCnBXZ7hqKngRpe20wPBudL_hvTKGX_qOP8t8DMQsKI0tka9j8W41Loukpg_5DQj0xmdaS6PTV__ThNbxs9E428ITyBl7YYhPWfzSW9U3Yv_AY1o89drUIyZr12D67WKBbP76Fh3Ntpqx0LLd0G8Rkfssms7Iq7yxrfEPYpGCoVjKcs0njaIuvXSoWPbg8DKe20rfYNOXWzHiMXuaP8LFuhzKC-UAWVt_WswXXp8Orb6Owub0hNKhVVbgxFWPcCzrNUyOM6-cpzxMdGUk6WBrZdGxiTNc27wtB3zpOrMxRfbEyTmQktmG1KAv7HphFLQvVNEfMiRACxy53lrsxbeayyEQBHLUTp-48SIfq4JjrMVc45orGXPEAvtDUKlrA1b02uolDwKYICksNSAeMEy5PAthdyokLzywnt8ShmoU_U7iDFqJPjwD2umQqSc5shS3ndR6CCcySLIB3nqi63xb1RcMnMoDjloQWlT_bp51_yv0BNjjRYB1RuQur1f3cfoSVWT7_1Kyl3zw6Eqc
link.rule.ids 315,782,786,27933,27934,41073,42142,48344,48347,48357,49649,49652,49662,52153
linkProvider Springer Nature
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwED7BJsFeYAwYgQ2MhAYbi5TF-eE8VrDSiW6aoEh7s1zHlqppybSmQvvvubOTlE7wAC9RIjtOYp_vPufuPgO8M7Gy5B4Ky5znYaJEFBY80qGKC4vmSYvIBWOOvudnF-LzMdHk8C4XxkW7dy5Jp6n7ZDcyRxT7I8KUVCvq3fWkyBIU5fXByeTLcKmAE8q99BcZAgDPxMwpjywVnWfzTy2u2Ka7Gvo3E3XHZ-pM0fDxf33EJjxqkScbeFF5AvdMtQUPTlvf-hbsnXsW69tDNlkmZc0P2R47X_Jb3z6Fn2OlL1ltWWloP4jZ4orN5nVTXxvWRoewWcUQWDIctVkbaounfSne-uHbfnhpGnWFj6baimnP0sv8T3xs26KVYD6Vhbn9ep7Bj-Hx5NMobPdvCDXiqgaXpnyKq0Gr4lxzbbMyj8tURVoQCssjk091guXKlBnndK2S1IgSAYwRSSoi_hzWqroyL4AZxFkI1CypJ-IInNrSmthOaTlXRDoK4KAbOXntaTpkT8js-lxin0vqcxkH8J7GVtIUbm6UVm0mAj6KyLDkgFBgksbiKICdlZo49fRqcScdsp36c4lraM4zOgTwti-mOymcrTL1wtUhosAiLQLY9lLVvzZ3Ww0fiQA-diK0bPyv3_Tyn2q_gYejyelYjk_Ovr6CjZjk0eVX7sBac7Mwu3B_Xi5etxPrF7ucFpc
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED-2Fspe9tF9eWs7DUb3VVPXsmP5qYQ1IduyErYW9iYUfUAotUPjMPrf786ynaZsD2MvIUayHEunu9_l7n4CeGNj5Sg8FJqMZ2GiRBTmPNKhinOH5kmLqE7GHP3ITn-KkwHR5By3tTB1tnsbkvQ1DcTSVFSHc-MOu8I3Mk2UByTClNQs6uDNBB0ZFPTN_uDLaLxSxgnVYfqLHoIBz8rMqaYsFW2U808jrtmp29r6hrm6FT-tzdLwwX-_0EO43yBS1vci9Aju2GIbtr41Mfdt2J94duvrA3a2KtZaHLB9NlnxXl8_hl9jpS9Y6ZixdE7EbHnJZouyKueWNVkjbFYwBJwMV3PWpODi164Vb333_X14YSt1iY-m3oppz97L_J_7OLZD68F8iQurz_F5AufDwdmnUdic6xBqxFsVuqx8il6iU3GmuXY9k8UmVZEWhM6yyGZTnWC7sqbHOV2rJLXCILCxIklFxJ_CRlEW9jkwi_gLAZwjtUXcgVNnnI3dlNy8PNJRAB_aVZRzT98hO6Lmes4lzrmkOZdxAG9pnSVt7epKadVUKOCjiCRL9gkdJmksjgLYWeuJW1KvN7eSIhuVsJDoW3Peo48AXnfNdCeluRW2XNZ9iEAwT_MAnnkJ6342r48gPhIBfGzFaTX4X9_pxT_1fgVbk5OhHH8-_foS7sUkjnXZ5Q5sVFdLuwt3F2a51-yx38kUH1o
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lack+of+deuterium+isotope+effects+in+the+antidepressant+effects+of+%28R%29-ketamine+in+a+chronic+social+defeat+stress+model&rft.jtitle=Psychopharmacology&rft.au=Zhang%2C+Kai&rft.au=Toki%2C+Hidetoh&rft.au=Fujita%2C+Yuko&rft.au=Ma%2C+Min&rft.date=2018-11-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=0033-3158&rft.eissn=1432-2072&rft.volume=235&rft.issue=11&rft.spage=3177&rft.epage=3185&rft_id=info:doi/10.1007%2Fs00213-018-5017-2&rft.externalDocID=10_1007_s00213_018_5017_2
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon